Reference number : GC-2017-Q4-01551, amendment number : , agreement type : G, recipient legal name : Rohani, Sohrab (The University of Western Ontario), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Crystallization is one of the oldest separation and purification unit operations in chemical industry. During this_x000D_
process, the atoms or molecules are transferred from solution to the solid phase and form solid crystals._x000D_
Conventionally, crystallization of fine chemicals and pharmaceuticals is conducted in batch mode to allow_x000D_
flexibility to respond to varying customized design requirements and changing market demands; however, this_x000D_
approach can also lead to increased manufacturing costs and batch-to-batch variations in product quality._x000D_
Recently, the development of continuous manufacturing and crystallization techniques has received increasing_x000D_
interest and research effort from academic and industrial sectors, due to the potential advantages of reduced_x000D_
costs, shorter development time, more robust scale-up and improved control performance._x000D_
Imatinib mesylate is a potent and selective inhibitor of the protein tyrosine kinase developed by Novartis. It_x000D_
was approved under the trade name "Gleevec/Glivec" by the US Food and Drug Administration (FDA) to treat_x000D_
Philadelphia chromosome positive chronic myelogenous leukemia (CML) in blast crisis, accelerated phase, or_x000D_
chronic phase after failure of interferon-alpha therapy and kit (CD117) positive unrespectable and/or metastatic_x000D_
malignant Gastro Intestinal Stromal Tumors (GISTs)._x000D_
Apotex PharmaChem Inc., as a generic pharmaceutical company is developing a continuous process for the_x000D_
manufacture of imatinib mesylate from 2018 when the patent of this drug is released._x000D_
The objective of this proposal is to design an effective continuous crystallization process for the production of_x000D_
this pharmaceutical from an organic solvent. The target crystal form is the metastable form with proper crystal_x000D_
size distribution. The metastable form is hygroscopic with needle like habit._x000D_
During the course of the project, the solubility of imatinib mesylate in a series of organic solvents and their_x000D_
mixture will be measured for solvent screening. The polymorphic transformation and nucleation and growth_x000D_
kinetics will be measured in a continuous mixed suspension mixed product removal crystallizer., program purpose french : Crystallization is one of the oldest separation and purification unit operations in chemical industry. During this_x000D_
process, the atoms or molecules are transferred from solution to the solid phase and form solid crystals._x000D_
Conventionally, crystallization of fine chemicals and pharmaceuticals is conducted in batch mode to allow_x000D_
flexibility to respond to varying customized design requirements and changing market demands; however, this_x000D_
approach can also lead to increased manufacturing costs and batch-to-batch variations in product quality._x000D_
Recently, the development of continuous manufacturing and crystallization techniques has received increasing_x000D_
interest and research effort from academic and industrial sectors, due to the potential advantages of reduced_x000D_
costs, shorter development time, more robust scale-up and improved control performance._x000D_
Imatinib mesylate is a potent and selective inhibitor of the protein tyrosine kinase developed by Novartis. It_x000D_
was approved under the trade name "Gleevec/Glivec" by the US Food and Drug Administration (FDA) to treat_x000D_
Philadelphia chromosome positive chronic myelogenous leukemia (CML) in blast crisis, accelerated phase, or_x000D_
chronic phase after failure of interferon-alpha therapy and kit (CD117) positive unrespectable and/or metastatic_x000D_
malignant Gastro Intestinal Stromal Tumors (GISTs)._x000D_
Apotex PharmaChem Inc., as a generic pharmaceutical company is developing a continuous process for the_x000D_
manufacture of imatinib mesylate from 2018 when the patent of this drug is released._x000D_
The objective of this proposal is to design an effective continuous crystallization process for the production of_x000D_
this pharmaceutical from an organic solvent. The target crystal form is the metastable form with proper crystal_x000D_
size distribution. The metastable form is hygroscopic with needle like habit._x000D_
During the course of the project, the solubility of imatinib mesylate in a series of organic solvents and their_x000D_
mixture will be measured for solvent screening. The polymorphic transformation and nucleation and growth_x000D_
kinetics will be measured in a continuous mixed suspension mixed product removal crystallizer., agreement title english : Continuous Crystallization for the Control of Solid-State Attributes of APIs, agreement title french : Continuous Crystallization for the Control of Solid-State Attributes of APIs, agreement number : EGP, agreement value : 25000.0, agreement start date : 2018-02-07, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada